- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | 1. lékařská fakulta
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | 1. lékařská fakulta
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a2021 | 1. lékařská fakulta
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer2017 | Lékařská fakulta v Hradci Králové
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study2015 | 1. lékařská fakulta